Kivorent News

Wednesday, November 18, 2026

Health techNews

White House withdraws Heidi Overton's nomination to lead the FDA

The White House pulled Heidi Overton's nomination for FDA commissioner on November 17, hours before a Senate HELP Committee vote. The FDA, which also regulates medical devices and AI software, has had no confirmed leader since May.

Docket, covering health regulation and AI in care
, 2 min read

210 daysacting-leader clock the withdrawal resets

What to know

  • The White House withdrew Heidi Overton's nomination on the evening of November 17, before a HELP Committee vote set for November 18.
  • Kyle Diamantas, the FDA's former deputy commissioner for food, has led the agency on an acting basis since Marty Makary left in May.
  • No replacement has been named; Semafor reported Sen. Roger Marshall (R-Kan.) is under consideration.

The White House withdrew Heidi Overton's nomination to be commissioner of the Food and Drug Administration on the evening of Tuesday, November 17. The Senate Health, Education, Labor and Pensions (HELP) Committee had scheduled a vote on her nomination for the next morning. Axios first reported the withdrawal, and CBS News, BioPharma Dive, Drug Topics and The Epoch Times confirmed it.

The FDA has not had a Senate-confirmed commissioner since Marty Makary left in May. Kyle Diamantas, who ran the agency's Human Foods Program as deputy commissioner for food, has been acting commissioner since then; The Epoch Times puts the start at May 15.

Why the nomination stalled

Overton, a physician who has served as a deputy assistant to the president for domestic policy, was announced as the nominee in August. The Senate received the nomination on September 14 and the HELP Committee held her hearing on September 24, according to The Epoch Times. She needed the vote of every Republican on the committee to advance, Drug Topics reported.

According to the reports, her support slipped over three issues. Some senators objected to her role in an August executive order to split the MMR vaccine into three separate shots and shorten the routine childhood vaccine schedule. Democrats pointed to her earlier criticism of the abortion pill mifepristone, while anti-abortion Republicans wanted firmer commitments on the FDA's ongoing mifepristone safety review. BioPharma Dive and CBS also cited her work loosening access to flavored vapes. Sen. Patty Murray (D-Wash.) said on November 10 that she would not support Overton.

HELP Committee chair Bill Cassidy (R-La.) said the White House told him Overton lacked the votes, but that he believed she would have cleared the committee and the full Senate. CBS reported he said the White House "abandoned a viable confirmation path."

What happens next

The White House has not named a new nominee. Semafor reported that Sen. Roger Marshall (R-Kan.), who lost his re-election race, is being considered, according to Food Safety Magazine and BioPharma Dive. Cassidy said confirming a permanent commissioner now appears to fall to Senate Democrats, who take control of the chamber in January.

Under the Federal Vacancies Reform Act an acting official can serve 210 days, and the withdrawal resets that clock, BioPharma Dive reported. That gives Diamantas room to keep running the agency into 2027.

Why it matters

The FDA commissioner sets direction for the agency that clears medical devices, including the AI software tools hospitals now buy. The leadership gap comes as the FDA rewrites how it talks about AI, under an executive order that had it switch to "Super Intelligence" terminology this week (our story), and as CMS pushes its own clinical SI roadmap that calls for close work with the FDA. Whoever is confirmed will also inherit the agency's pending draft policy on generative AI devices. The mifepristone review also bears on whether the pill can keep being prescribed by telehealth and mailed, a question we covered in our explainer on telehealth prescribing rules. For how the agency's device review works, see our explainer on FDA clearance, approval and De Novo.

This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.

Sources

FDA and health regulationDigital health and AI in careAI law and policy

Written by an AI correspondent under standards set by editor Jacob Knight. Spotted an error? Tell us and we will fix it.